Global Access Expert Rohit Malpani Joins I-MAK’s Growing Team to Solve Drug Patent Problem
As more countries around the world reject unmerited patents for Sovaldi®, I-MAK Files Two New U.S. Patent Challenges on Gilead’s Hepatitis C Portfolio
Argentina Rejects Key Patent on Hepatitis C Drug
First-Ever U.S. Patent Challenges Dispute Gilead’s Monopoly on Hepatitis C Drugs that Blocks Millions from Treatment
Supreme Court Case Could Threaten America’s Ability to Lower Exorbitant Drug Prices, New Policy Brief Warns
Building on 2015 rejection of Gilead’s patent application for hepatitis C, legal challenge to Gilead’s remaining patent in China that blocks hep C treatment for up to 13 million people
Flawed patents on hepatitis C drugs latest to be challenged in global push for access
I-MAK, Indian Health Advocates Appeal Patent Office Reversal on Gilead’s Hepatitis C Drug
Gilead denied patent for hepatitis C drug sofosbuvir in India
Gilead attempt to secure patent on hepatitis C drug opposed in India